[
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb Remains Undervalued In 2025",
    "summary": "Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.",
    "url": "https://finnhub.io/api/news?id=ef870d0978205ddbda040a9c799af982910929083ae52e5bd46e2219a463e9b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763457986,
      "headline": "Why Bristol-Myers Squibb Remains Undervalued In 2025",
      "id": 137537841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/937153960/image_937153960.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.",
      "url": "https://finnhub.io/api/news?id=ef870d0978205ddbda040a9c799af982910929083ae52e5bd46e2219a463e9b2"
    }
  },
  {
    "ts": null,
    "headline": "It's Best Time In 10 Years To Lock In Income: Our Picks",
    "summary": "Discover top REITs, dividend ETFs, and midstream picks yielding 3.5â7%+ with lower risk.",
    "url": "https://finnhub.io/api/news?id=152a955670b3094411135e44f8f6949d3073003d85115c348cc30929ddc35a4e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763456400,
      "headline": "It's Best Time In 10 Years To Lock In Income: Our Picks",
      "id": 137537735,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1938074854/image_1938074854.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover top REITs, dividend ETFs, and midstream picks yielding 3.5â7%+ with lower risk.",
      "url": "https://finnhub.io/api/news?id=152a955670b3094411135e44f8f6949d3073003d85115c348cc30929ddc35a4e"
    }
  }
]